Ulka Vaishampayan

Ulka Vaishampayan

Ulka Vaishampayan

Position Title

Professor
Division Head, Solid Tumor Oncology
Hematology-Oncology

Office Location

Karmanos Cancer Institute
4100 John R.
Hudson-Webber Cancer Research Center
Mail Code: HW04HO
Detroit, MI 48201

Office Phone

(313) 576-8718

Office Fax

(313) 576-8487

Education Training

Education
(1993)  M.B.B.S., Byramjee Jeejeebhoy Medical School, Pune, India
(1987)  B.S., Undergraduate, Fergusson College

Postgraduate Training
(1999-2000)  Chief Fellow, Hematology/Oncology, Wayne State University, Detroit, MI
(1997-2000)  Hematology/Oncology Fellowship, Wayne State University, Detroit, MI
(1994-1997)  Residency in Internal Medicine, Wayne State University, Detroit, MI

Professional Experience

Faculty Appointments
(2014-Present)  Phase I Program Chair, Karmanos Cancer Institute, Detroit, MI
(2005-Present)  GU Multidisciplinary Chair, Karmanos Cancer Institute, Detroit, MI
(2000-Present)  Detroit Medical Center/Barbara Ann Karmanos Cancer Institute, Detroit, MI
(2008-2011)  Chair, Medical Records, Karmanos Cancer Center
(2006-2010)  Secretary and Treasurer, Medical Staff Leadership Committee, Karmanos Cancer Institute
(2004-2009)  Member, Pharmacy and Therapeutics Hematology/Oncology subcommittee

Major Professional Societies

(2004-Present) Southwest Oncology Group - GU Committee
(1998-Present) American Society of Clinical Oncology (ASCO) Member
(2012-2015)  American Society of Clinical Oncology (ASCO) CME subcommittee
(2010-2012)  American Society of Clinical Oncology (ASCO) Scientific committee GU track
(2008-2011)  Chair, GU group of the NCI Phase II clinical trial consortium

Board Certification

(2000)  Certified, Medical Oncology
(2001)  Certified, Hematology  
(1997)  Certified, Internal Medicine 

Honors and Awards

(2012)  Teacher of the Year award, Hematology/Oncology Fellowship program
(2011-2012)  Wayne State University School of Medicine College Teaching Award
(2012)  Best Doctors
(2011)  Hour Magazines Best Doctors in America award
(2010)  Hour Magazines Best Doctors in America award
(2009)  Hour Magazines Best Doctors in America award
(2009) Teacher of the Year award in Oncology from the graduating Fellows of the Division of Hematology/Oncology, Wayne State University
(2008)  Nominated for the teaching award at Wayne State University
(2004)  Nominated for the research award at Wayne State University
(2004) Wayne State University School of Medicine College Teaching Award, Awarded by the Dean of Wayne State University School of Medicine & the Executive Committee
(2000)  ASCO Travel Award for Poster presentation at the American Society of Clinic: Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and
Radiation Therapy in Locally Advanced, Recurrent or Unresectable Urothelial Carcinoma.
(1999)  American Society of Clinical Oncology Merit Award May 1999: "Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine in Advanced Urothelial Carcinoma."   
(1996) First Place-Best Oral Presentation Research: "Differentiation therapy of a case of Small Lymphocytic Lymphoma by Bryostatin," American College of Physicians Michigan Chapter, Eighteen Annual Associate Meeting, American College of Physicians Meeting
(1985-1992)  National Talent Scholarship
(1985-1987)  Undergraduate College : Graduated with Distinction, (top 1% in the state)

Courses taught

Medical Resident Instruction

Research Interests

- Clinical Trials in genitourinary cancers (prostate, testis, adrenal, kidney and bladder /urothelial cancers)
- Predictive markers to help guide therapy
- Disparity research in disease coure, treatments and outcomes

As a medical oncologist who treats predominantly genitourinary cancers, my overall goal is  to improve upon the current treatments for prostate, kidney, bladder and testis cancers. Besides excellemnt clinical management, I am a firm believer in clinical trials as a pathway to progress. I have developed, conducted and successfully completed and reported multiple clinical trials in GU cancers.In addition, to narrow the disparities in treatment, I have developed better tolerated and easily accessible therapies for specific populations. I have developed the easily tolerated and effective regimen of concurrent capecitabine and radiation for treatment of bladder cancer in elderly patients or in patients with multiple medical problems who cannot tolerate conventional therapies. In advanced prostate cancer I am interested in regimens to overcome resistance and to improve efficacy. In kidney cancer, I have working  on numerous novel therapies through clinical trial participation  and am now working on a predictive marker panel to help customize  therapy selection.

 

Publications

1. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25 PMID:23550669

2. Vaishampayan U, Heilbrun L, Smith D, Baranowski K, Dickow B, Figg W. Phase II trial of satraplatin and bevacizumab in metastatic docetaxel pretreated castrate resistant prostate cancer. Urol Oncol. 2013 Feb 20. S1078-1439. PMID:23433892

3. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma.  J Clin Oncol. 2013 Jan 10;31(2):181-6. Doi: 10.1200/JCO.201243.3383, Epub 2012 Dec 3. PMID:23213094 [PubMed-in process]

4. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schӧffski P, Scheffold C, Weitzman AL, Hussain M.  Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol. 2013 Feb 1; 31(4):412-9 doi: 10.1200/JCO.2012.450494, Epub 2012 Nov 19. PMID:23169517 (in process)

5. Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba N, Egorin MJ, Ivy P, Pacey S, Lorusso P. Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin. Clin Cancer Res. 2010 Jun 4. [Epub ahead of print].  PMID: 20525756.

6.Tripathi RT, Heilbrun LK, Jain V,  Vaishampayan UN.  Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma.  Urology. 2006 Aug; 68(2):296-301. *

7. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.  Phase II Trial of Carboplatin and Paclitaxel in Cisplatin Refractory Advanced Transitional Cell Carcinoma: A Southwest Oncology Group Study.  Cancer,  104(8):1627-32, 2005.

8.  Patel B*., Forman J., Fontana J., Frazier A., Pontes E.,  Vaishampayan U.  A Single Institution Experience With Concurrent Capecitabine And Radiation Therapy In Weak And/Or Elderly Patients With Urothelial Carcinoma. Int Rad Onc Biology Physics, 62(5)1332-8, 2005. *

9. Vaishampayan U., Ben-Josef E., Philip P., Vaitkevicius V.K., Du W., Levin K.J., Shields, AF.   A single institution experience of concurrent capecitabine and radiation in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 53(3): 675-679, 2002.

10.  Hussain M.,  Vaishampayan U., Du W., Redman B., Smith D.  Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol , 19(9):2527-33, 2001. patient accrual, data collection and manuscript review

 

Faculty Status

Hem-Onc, Department Leadership

← Return to listing